Thema: US83422E2046
SLDB, US83422E2046
financial-2860753_1920.jpg - Foto: THN
Solid Biosciences stock advances SGT-212 regulatory path
Solid Biosciences stock remains in focus after an EU orphan designation for SGT-212. The company also reported progress in its FALCON trial.
ad-hoc-news.de, heute 01:12 Uhr
SLDB, US83422E2046
Solid Biosciences stock: H.C. Wainwright keeps USD 25.00 ...
Five FALCON participants had received SGT-212 by October 5, 2026. The Q1 2027 data milestone concerns Solid Biosciences stock.
ad-hoc-news.de, 28.10.26 07:19 Uhr
SLDB, US83422E2046
Solid Biosciences presents seven studies. Solid Biosciences ...
Seven studies are scheduled for ESGCT from October 27, 2026. Solid Biosciences stock was last at USD 6.40 on Nasdaq October 20, 2026.
ad-hoc-news.de, 21.10.26 00:20 Uhr
SLDB, US83422E2046
UBS initiated coverage of Solid Biosciences stock with USD ...
UBS set a USD 20.00 target on October 14, 2026. Solid Biosciences stock last stood at USD 5.74 on Nasdaq after hours on October 15, 2026.
ad-hoc-news.de, 16.10.26 03:46 Uhr
SLDB, US83422E2046
Solid Biosciences stock fell 1.98 percent after Q2 EPS beat ...
Solid Biosciences stock was last at USD 6.92 on October 6, 2026, with a USD 681.3 million market value. Q2 EPS beat consensus by USD 0.08.
ad-hoc-news.de, 07.10.26 05:37 Uhr
SLDB, US83422E2046
Solid Biosciences stock fell 1.86 percent on October 2
